Head and Neck Squamous Cell Carcinoma - Opportunity Analysis and Forecast to 2026

Tuesday, July 10, 2018 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, July 10, 2018 /PRNewswire/ -- Head and Neck Squamous Cell Carcinoma - Opportunity Analysis and Forecast to 2026Download

the full report: https://www.reportbuyer.com/product/5471679 SummaryThe recent surge in investment in Head and Neck Squamous Cell Carcinoma (HNSCC) has resulted in an innovative pipeline. Because it is an area with high unmet need and little
competition, pharmaceutical companies of varying sizes are attempting to capture their own share of this potentially lucrative market.There are currently no known biomarkers for Head and Neck Squamous Cell Carcinoma (HNSCC) that can reliably predict patient response to drug treatment.This is expected to become an important issue as expensive immunotherapies are increasingly incorporated into the Head and Neck Squamous Cell Carcinoma (HNSCC) treatment algorithm.Predictive biomarkers will become especially important as the cost of treatment is increasingly becoming an issue for payers. With the controversially high cost of new cancer therapies, there is a greater need for better patient screening in order to identify patients who are most likely to respond to, and who would benefit the most from, targeted therapies.While the pipeline agents under investigation are expected to address the main unmet needs in the Head and Neck Squamous Cell Carcinoma (HNSCC) space by decreasing the toxicity of current regimens for rmHNSCC and reducing the risk of recurrence in LA-HNSCC patients, KOLs reported a substantial unmet need for the identification of new druggable targets. Understanding the molecular or genetic basis for disease development would do much to improve patient care by helping developers to identify new druggable targets and helping physicians to identify patients who are more likely to benefit from specific treatmentsResearchers expect that total Head and Neck Squamous Cell Carcinoma (HNSCC) market is expected to experience significant growth between 2016 and 2026; with drug sales in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) will increase to $3.6B in 2026, at a Compound Annual Growth Rate (CAGR) of 20.1%.The main growth drivers will be attributed to the incorporation of immune-checkpoint inhibitors into the first-line recurrent/metastatic and locally-advanced disease treatment paradigms. Due to the high cost of immunotherapy regimens, this is expected to cause large growth within the head and neck cancer market.Scope- Overview of HNC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.- Annualized HNC therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven patient segments, forecast from 2016 to 2026.- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the HNC therapeutics market.- Overview of HNC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.- Annualized HNC therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven patient segments, forecast from 2016 to 2026.- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the HNC therapeutics market.Reasons to buyThe report will enable you to -- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.- Develop business strategies by understanding the trends shaping and driving the global HNC market.- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HNC market in the future.- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.Download the full report: https://www.reportbuyer.com/product/5471679 About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: sarah@reportbuyer.com Tel: +1 (718) 213 4904 Website: www.reportbuyer.com

Cision View original content:http://www.prnewswire.com/news-releases/head-and-neck-squamous-cell-carcinoma---opportunity-analysis-and-forecast-to-2026-300678755.html

SOURCE ReportBuyer



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store